Literature DB >> 10775459

Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site.

H Iber1, Q Chen, P Y Cheng, E T Morgan.   

Abstract

Inflammatory cytokines cause the down-regulation of multiple cytochrome P450 mRNAs, but the transcriptional mechanisms involved are not known. We investigated the role of a putative negative NF-kappaB-responsive element, nkappaB-RE1, in the down-regulation of the CYP2C11 gene in rat hepatocytes. This sequence spans the transcription start site of CYP2C11, from positions -2 to +8. Electrophoretic mobility shift assays showed that nuclear extracts from livers of rats treated with bacterial lipopolysaccharide, or from hepatocytes treated with interleukin-1beta, formed a protein complex with an oligonucleotide probe containing the nkappaB-RE1, and that this complex contained predominantly the p50 subunit of NF-kappaB. Binding of NF-kappaB to the nkappaB-RE1 probe was of lower affinity than to a probe containing the prototypic NF-kappaB enhancer of the immunoglobulin kappa chain gene. Mutations in the 5'-end of the nkappaB-RE1, and to a lesser extent the 3'-end, reduced the affinity of NF-kappaB for this element. Introduction of the 5'-mutation into nkappaB-RE1 abolished the response of the -200-CYP2C11-chloramphenicol acetyltransferase reporter construct to interleukin-1 or lipopolysaccharide. We conclude that nkappaB-RE1 is a functional negative regulatory element that participates in the inflammatory suppression of CYP2C11. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775459     DOI: 10.1006/abbi.2000.1772

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  13 in total

Review 1.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

2.  Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model.

Authors:  Hong Wu; Zhihua Liu; Guoyu Ling; David Lawrence; Xinxin Ding
Journal:  Toxicol Sci       Date:  2013-07-24       Impact factor: 4.849

3.  Regulation of cytochrome P450 4F11 by nuclear transcription factor-κB.

Authors:  Jordan C Bell; Henry W Strobel
Journal:  Drug Metab Dispos       Date:  2011-10-19       Impact factor: 3.922

4.  Functional characterization of the NF-kappaB binding site in the human NOD2 promoter.

Authors:  Chaofeng Hu; Liping Sun; Yiling Hu; Daxiang Lu; Huadong Wang; Suisheng Tang
Journal:  Cell Mol Immunol       Date:  2010-05-03       Impact factor: 11.530

5.  Treprostinil Improves Hepatic Cytochrome P450 Activity during Rat Liver Transplantation.

Authors:  Nisanne Ghonem; Junichi Yoshida; Noriko Murase; Stephen C Strom; Raman Venkataramanan
Journal:  J Clin Exp Hepatol       Date:  2012-10-12

Review 6.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 7.  Eicosanoids and renal damage in cardiometabolic syndrome.

Authors:  John D Imig
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-02       Impact factor: 4.481

8.  Increased CYP4B1 mRNA is associated with the inhibition of dextran sulfate sodium-induced colitis by caffeic acid in mice.

Authors:  Zhong Ye; Zhiping Liu; Abigail Henderson; Kwangwon Lee; Jesse Hostetter; Michael Wannemuehler; Suzanne Hendrich
Journal:  Exp Biol Med (Maywood)       Date:  2009-03-23

9.  Augmenter of liver regeneration.

Authors:  Chandrashekhar R Gandhi
Journal:  Fibrogenesis Tissue Repair       Date:  2012-07-09

10.  The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.

Authors:  Robert N Schuck; Weibin Zha; Matthew L Edin; Artiom Gruzdev; Kimberly C Vendrov; Tricia M Miller; Zhenghong Xu; Fred B Lih; Laura M DeGraff; Kenneth B Tomer; H Michael Jones; Liza Makowski; Leaf Huang; Samuel M Poloyac; Darryl C Zeldin; Craig R Lee
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.